Peptide Comparison
BPC-157vsUrocortin
The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.
A powerful stress-response peptide that protects your heart and helps your body handle pressure
At a Glance
Quick
comparison
Dose Range
BPC-157
250–500 mcg
Urocortin
36–360 pmol/min
Frequency
BPC-157
Once daily
Urocortin
Once daily
Administration
BPC-157
Subcutaneous injection
Urocortin
As directed by healthcare provider
Cycle Length
BPC-157
4-6 weeks
Urocortin
Ongoing/indefinite
Onset Speed
BPC-157
Moderate (1-2 weeks)
Urocortin
Moderate (1-2 weeks)
Evidence Level
BPC-157
Strong preclinical (extensive animal studies)
Urocortin
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Primary Benefit
Secondary Benefit
Additional Benefit
Cardiovascular Protection
Stress Response & Resilience
Heart Function Support
Technical Data
Compound
specifications
BPC-157
Molecular Formula
C62H98N16O22
Molecular Weight
1419.53 g/mol
Half-Life
4-6 hours
Bioavailability
~100% (subcutaneous)
CAS Number
137525-51-0
Urocortin
Molecular Formula
C216H329N59O64S
Molecular Weight
Approximately 4,700 Daltons
Half-Life
Approximately 2-6 hours (varies by route of administration)
Bioavailability
Varies by route of administration
CAS Number
173190-76-4
Protocols
Dosing
tiers
BPC-157
Urocortin
Applications
Best
suited for
BPC-157
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms
Urocortin
Supporting cardiovascular health during stressful periods
Urocortin is particularly well-suited for individuals focused on supporting cardiovascular health during stressful periods. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Improving heart function in those with weakened hearts
Urocortin is particularly well-suited for individuals focused on improving heart function in those with weakened hearts. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Enhancing stress resilience and coping
Urocortin is particularly well-suited for individuals focused on enhancing stress resilience and coping. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Optimizing blood vessel and circulation function
Urocortin is particularly well-suited for individuals focused on optimizing blood vessel and circulation function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety Profile
Side
effects
BPC-157
Common
- Injection site redness
- Mild nausea
- Dizziness
Uncommon
- Headache
- Fatigue
- Hot/cold sensations
Serious
- Allergic reaction
Urocortin
Common
- Facial flushing
- Mild headache
- Dizziness
- Injection site response
- Nausea
Serious
- Severe allergic reaction
- Severe blood pressure changes
- Heart palpitations
Research Status
Safety
& evidence
BPC-157
Evidence Level
Strong preclinical (extensive animal studies)
FDA Status
Research compound
Safety Overview
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
Contraindications
- xPregnancy
- xBreastfeeding
- xActive cancer
- xHistory of cancer
Urocortin
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Urocortin III (a corticotropin-releasing factor analogue) shows preclinical safety in animal models with potential CNS and cardiovascular effects through CRF receptor activation. No completed human clinical trials exist—all human data comes from limited Phase 1 safety/tolerability work in small populations. Expected adverse effects based on CRF physiology include anxiety/panic-like symptoms (paradoxical, due to CRF's role in stress response), hypothalamic-pituitary-adrenal (HPA) axis effects, and cardiovascular responses (blood pressure, heart rate changes). Neurotoxicity and excitotoxicity are theoretical concerns requiring electrolyte and cardiac monitoring.
Contraindications
- xHypersensitivity to urocortin or CRF-related peptides
- xSevere hypertension without medical monitoring
- xAcute coronary syndrome (heart attack) - requires careful evaluation
- xUncontrolled arrhythmias
- xPregnancy and breastfeeding (limited safety data)
Decision Guide
Which is
right for you?
Choose BPC-157 if...
- Injury recovery
- Post-surgery healing
- Chronic pain management
- Gut health
Choose Urocortin if...
- Supporting cardiovascular health during stressful periods
- Improving heart function in those with weakened hearts
- Enhancing stress resilience and coping
- Optimizing blood vessel and circulation function